TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Use of Repetitive Facilitative Exercise Program in Established Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 years~* Having a single ischemic or hemorrhagic hemispheric stroke of more than 6 months duration~* The ability to selectively demonstrate active extension of at least 10 degrees at the metacarpo-phalangeal joint and the interphalangeal joints and 20 degrees at the wrist~* Capable of effectively participating in the study~Exclusion Criteria:~* Upper extremity contracture/pain that interfere with study technique~* Pre-existing upper extremity neurologic or orthopedic disorders~* Unstable medical condition~* BMI \> 35~* Active treatment of condition during 3 months prior to enrollment in study (botulinum toxin, therapy, tendon release, etc.)~* Language or cognitive/perceptual deficits or scheduling problems that would limit participation~* Inability to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Repetitive Facilitative Exercise (Type: EXPERIMENTAL): Occupational therapy program - Repetitive facilitative exercise therapy protocol including 40 min of RFE and 20 minutes of task-specific activity. 3 treatment sessions weekly for a total of 4 weeks.
- Conventional Therapy Program (Type: NO_INTERVENTION): Typical therapy excluding robotics, RFE

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Short Spot Versus Long Lesion Stenting as Best Treatment for Extensive Occlusive SFA Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* PAOD (ABI \<0.90 and/or a decline of \>0.15 after exercise test), Rutherford category 2, 3 or 4~* Multiple (\>1) short (focal; \>1 and \< 5 cm) significant stenoses (≥ 50%) and/or occlusions in the superficial femoral artery~* Eligible for endovascular treatment via short spot stenting and via long lesion stenting according to international guidelines~* Unilateral occlusive disease~* Age ≥ 18~Exclusion Criteria:~* Patients with PAOD Rutherford category 5 and 6~* Impaired inflow due to significant lesions in the arteries proximal to the SFA intended to treat~* Bilateral lesions with treatment indication~* Contra-indication for anticoagulant therapy~* Renal insufficiency (MDRD \< 50 ml/min)~* Life expectancy \< 6 months~* Known contrast allergy~* Pregnancy~* Unable to complete a questionnaire in the home language

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Short spot stenting (Type: EXPERIMENTAL): Short spot stenting
- Long lesion stenting (Type: EXPERIMENTAL): Long lesion stenting

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recurrent epithelial ovarian cancer or primary peritoneal carcinoma that can be platinum sensitive or platinum resistant~* SWOG Performance Status 0-2~* Previously received a platinum and paclitaxel containing regimen~* Projected Life Expectancy of at least 3 months~* Adequate bone marrow function~* Adequate organ function~* Must have received at least 1 prior salvage regimen for recurrent ovarian cancer~* Recovery from acute toxicities from surgery, radiation or chemotherapy~* At least 3 weeks from last therapy~Exclusion Criteria:~* Prior fenretinide oral capsule use allowed. If prior IV fenretinide use, must contact study chair for eligibility~* Second malignancy within last 5 years~* Use of concomitant antioxidants, such as vitamin C or E~* Untreated or symptomatic brain metastases~* History of hypertriglyceride levels \> 200 mg/dl; triglyceride levels \< 200 and receiving treatment are okay.~* Use of certain medications is prohibited - contact study coordinator for information

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fenretinide/LXS + Ketoconozale (Type: EXPERIMENTAL): One course is defined as 7 days of Fenretinide/LXS + Ketoconazole followed by 14 days of rest. A course is repeated every 21 days if no evidence of disease progression for six courses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with stable tachycardia ≥120 lpm, QRS ≥120 ms and haemodynamically well tolerated defined as: 1)Systolic blood pressure ≥90 mmHg, 2) absence of dyspnea at rest, 3)absence of peripheric hypoperfusion signs and 4)no severe angina.~* Age \> 18 years~* Written inform consent obtained~Exclusion Criteria:~* Treatment with iv amiodarone or iv procainamide during the previous 24 hours~* QRS tachycardia \<120 ms~* Patients with QRS ≥120 ms tachycardia with haemodynamic compromise that requires urgent cardioversion for termination~* Irregular tachycardia~* Tachycardia that is considered as supraventricular due to physician criteria (adenosine and/or vagal manoeuvres response)~* Patient that do not want to cooperate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): IV procainamide (single dose: 10 mg/kg over 20 min)
- Group 2 (Type: ACTIVE_COMPARATOR): IV Amiodarone (single dose: 5 mg/kg over 20 min)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Locally advanced or metastatic NSCLC~* EGFR mutation (L858R and /or ex19del)~* cMET amplification by FISH (GCN ≥ 6),~* Acquired resistance to EGFR TKI (1st or 2nd generation)~* ECOG performance status (PS) ≤ 1.~Exclusion Criteria:~* Prior treatment with 3rd generation TKI~* PhaseII : Prior treatment with any of the following agents:~  * Crizotinib, or any other cMET inhibitor or HGF-targeting inhibitor.~ * Concomitant EGFR TKI and platinum based chemotherapy as first line regimen.~ * Platinum-based chemotherapy as first line treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- INC280 200mg BID + ERL 150mg QD (Type: EXPERIMENTAL): Subjects who took INC280 200mg twice a day (BID) in combination with erlotinib (ERL) 150mg one a day (QD)
- INC280 400mg BID + ERL 150mg QD (Type: EXPERIMENTAL): Subjects who took INC280 400mg twice a day (BID) in combination with erlotinib (ERL) 150mg one a day (QD)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent (IC)~* Age ≥ 40 years~* History of COPD for at least 12 months prior to enrollment (Visit V0)~* Chronic productive cough for 3 months in each of the 2 years prior to enrollment (if other causes of productive cough have been excluded) and/or an exacerbation with predominantly bronchitic symptoms at enrollment~* Presentation of an acute exacerbation of COPD that will be associated with increased sputum volume or change in sputum colour~* Documented fixed airway obstruction determined by an FEV1/FVC ratio (post-bronchodilator) \< 70% (if a pulmonary function test is not possible at Visit V0 a previous measurement can be taken which must not be older than 6 months)~* Former smoker (defined as: smoking cessation at least 1 year ago) or current smoker both with a smoking history of at least 10 pack years~Main Exclusion Criteria:~* Diagnosis of asthma and/or other relevant lung disease~* Known alpha-1-antitrypsin deficiency~* Recurrent exacerbations (within 8 weeks of a preceding exacerbation)~* Treatment of current exacerbation with oral corticosteroids and/or antibiotics already started at enrollment~* Treatment with PDE4 inhibitors within 3 months prior to Visit V0~* Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Roflumilast (Type: ACTIVE_COMPARATOR): added on to standard therapy for acute COPD exacerbations
- Placebo (Type: PLACEBO_COMPARATOR): added on to standard therapy for acute COPD exacerbations

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* colorectal cancer above to 12 cm from the anal verge~* unresectable synchronous metastases~* no contraindications for chemotherapy~* absence of peritoneal carcinomatosis, central nervous system o bone metastasis.~* performance status ECOG ≤ 2 (Eastern Cooperative Oncology Group)~* uncontrolled concomitant medical conditions that may compromise to chemotherapy~* significant symptomatic cardiac disease~* not pregnancy or breastfeeding~Exclusion Criteria:~* Cases of rectal tumours below 12cm from anal verge, or locally advanced tumours invading blood vessels, nerves or bone.~* Multiple bone metastasis or central nervous system metastasis~* Other neoplastic disease in the 5 previous years, except squamous or basal cell skin carcinoma or cervical in situ carcinoma~* Significant heart disease (chronic congestive heart failure, symptomatic coronary disease) or myocardial infarction in the previous 6 months~* Peripheral neuropathy~* Patients who do not give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- colonic resection (Type: EXPERIMENTAL): Arm A (experimental): surgery (complete tumoral resection; R0) followed by chemotherapy, regimen according to each center.
- Chemotherapy (Type: ACTIVE_COMPARATOR): Arm B (control): chemotherapy alone, regimen according to each center

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D and Walking Ability in Patients With Peripheral Artery Occlusive Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* peripheral artery obliterative disease Rutherford 1 to 3~* informed consent~* motivation~Exclusion Criteria:~* inability of treadmill walking~* not motivated~* female patients: childbearing age (age limit 49 years)~* PTA or surgical revascularisation within 3 months before study entry~* cancer, life expectancy lower than 6 months~* ongoing therapy with Vitamin D~* 25-OH-Vitamin D level 125 nmol/l and above~* contraindications for Vitamin D intake (sarcoidosis, acute lung tbc, hypercalcemia, intake of Vitamin D analogs~* contraindications for ultrasound contrast agent (known hypersensitivity, recent acute coronary syndrome, unstable ischemic heart disease, after PTCA, heart insufficiency NYHA III or IV, severe rhythm disorders, known right- left shunt, severe pulmonary artery hypertension, adult respiratory distress syndrome

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitamin D (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Digital Sedation: Virtual Reality Hypnosis During Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 18 years or older~* Indication for screening or diagnostic colonoscopy under conventional IVS (propofol)~* Provision of written informed consent~Exclusion Criteria:~* Scheduled dilation~* Active Crohn Disease~* Low auditory acuity that precludes use of the device~* Low visual acuity that precludes use of the device~* Head or face wounds precluding use of the device~* Schizophrenia~* Dizziness~* Water/sea phobia~* Non-proficiency in French or Dutch (research language)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Digital Sedation (Type: EXPERIMENTAL): Digital Sedation with rescue intravenous sedation (propofol) if needed upon patient request
- Intravenous sedation (Type: ACTIVE_COMPARATOR): Control arm with conventional Intravenous sedation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Stable and Independent Communication Brain-computer Interfaces

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria for healthy persons:~* Older than 18~* Fluent in French, English, German or Italian~* Good visual acuity~Inclusion criteria for people with tetraplegia:~* Older than 18~* Fluent in French, English, German or Italian~* Good visual acuity~* Diagnosed with spinal cord injury, brainstem stroke, spinal stroke, muscular dystrophy or other non-degenerative motor neuron disorders~* Limited or no ability to use both hands - less than grade 4 muscle strength in elbow extension and wrist extension and less than grade 2 strength in finger flexor and abduction on both sides~Inclusion criteria for people with locked-in syndrome:~* Were fluent in French, English, German or Italian before losing the ability to speak~* Enough visual capability to see large letters from a distance of around 50cm according to caretaker's or guardian's opinion~Exclusion criteria for healthy persons:~* Smokers~* Substance or alcohol abuse~* Neurological or psychiatric illness~* History of cranio-facial surgery~* Metallic implants that would prohibit the subject from having a MRI scan~* Medications that may retard motor coordination and cognitive ability (such as sedatives)~* Seizure disorders~* Treated with anti-epileptic medications~Exclusion criteria for people with tetraplegia and locked-in syndrome:~* Disabling neurological illness other than tetraplegia or locked-in syndrome~* Disabling psychiatric illness~* History of cranio-facial surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Stable and Independent Communication Brain-computer Interfaces (Type: EXPERIMENTAL): Each arm will receive the same intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Costs, Efficiency and the Role of Management in HIV Prevention Interventions for Female Sex Workers in Nigeria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clusters: community-based organizations that serve female sex workers under Society for Family Health, through the SHIPs or Global Fund grants~* Participants: managers (officers) that oversee the functions of the organization and supervise volunteer staff~Exclusion Criteria:~* Clusters: excludes organizations not serving female sex workers and not working under Society for Family Health, through Global Fund or SHIPs grants~* Participants: excludes anyone not explicitly working as a manager overseeing volunteer implementation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment: Management + data training (Type: EXPERIMENTAL): The treatment group in the study will receive a 5-day training. The first two days of the training will consist of introducing the data collection tools and collecting baseline data. Days three through five of the training will consist of a variety of management topics.~On a monthly basis, the treatment group will receive data visualizations that will compare their site's performance that month to pervious performance and to other sites in the study. Both treatment and control groups will collect information regarding input costs and number of services provided on a monthly basis.
- Control: data training only (Type: NO_INTERVENTION): The control group will receive only a 2-day training which will focus on data collection alone. Both treatment and control groups will collect information regarding input costs and number of services provided on a monthly basis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Acetic Acid Chromoendoscopy in Barrett's Esophagus Surveillance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years and older~* Previous diagnosis of Barrett's esophagus, confirmed by pathology.~Exclusion Criteria:~* Patients diagnosed with any level of dysplasia on previous esophageal biopsies.~* Patients who had esophageal therapy with Halo radiofrequency ablation in the past, or esophagectomy.~* History of allergy to Acetic Acid~* History of esophageal dysplasia or cancer~* Esophageal ulcerations~* Esophageal Candida~* Esophageal Varices~* Patients with active esophagitis~* Patients who cannot provide a valid consent~* Patients who are currently pregnant

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Chromoendoscopy using Acetic Acid 2.5% (Type: EXPERIMENTAL): Patient will have endoscopic examination of esophagus. Esophageal mucosa sprayed with 5cc solution of Acetic Acid 2.5% one time only. Esophageal mucosa examined again. Biopsies are obtained. Abnormal areas identified by Acetic Acid 2.5% will be submitted on separate containers for pathology review. If no abnormalities seen, random biopsies taken as per standard recommendations for Barrett's esophagus. Samples submitted for pathology review.
- Standard random esophageal biopsies (Type: ACTIVE_COMPARATOR): Patient will have endoscopic examination of the esophagus. Esophageal mucosa will not be sprayed with Acetic Acid 2.5%. Random biopsies taken as per standard recommendations for Barrett's esophagus. Samples submitted for pathology review.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Aprepitant for Patients Receiving Carboplatin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* No prior chemotherapy~* Confirmed malignancy, scheduled to receive carboplatin monotherapy, or carboplatin in combination with agents of minimal, low, or moderate emetic potential~* Laboratory parameters adequate for chemotherapy~Exclusion Criteria:~* Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 3 or 4~* Presence of nausea and vomiting or use of major antiemetic agents during the 24 hours before chemotherapy administration~* Patients receiving radiotherapy within 5 days prior to the carboplatin~* Pregnancy or lactation~* Known allergy to any of the 3 antiemetics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- low dose aprepitant or fosaprepitant (Type: EXPERIMENTAL): In addition to standard prophylactic antiemetics (Ondansetron 16mg and Dexamethasone 20mg) patients will be given aprepitant 125mg orally or 115mg fosaprepitant intravenously prior to the first cycle of carboplatin-based chemotherapy. No medications will be given afterwards

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval